Volume 20, Issue 1 (Paramedical Sciences and Military Health 2025)
Paramedical Sciences and Military Health 2025, 20(1): 56-70 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Pezeshki M, Eshragi H, Nakhaee M. The Importance of Next-Generation Sequencing Panels in Diagnosing and Treating Lung Cancer through a Personalized Medicine Approach. Paramedical Sciences and Military Health 2025; 20 (1) :56-70
URL: http://jps.ajaums.ac.ir/article-1-449-en.html
URL: http://jps.ajaums.ac.ir/article-1-449-en.html
1- MSc in Genetics, Development and Research Group of LifeandMe Company, Tehran, Iran. , medcare.lifeandme@gmail.com
2- Nutrition Science Specialist, LifeandMe Company, Tehran, Iran.
3- BSc in laboratory science, Development and Research Group of LifeandMe Company, Tehran, Iran.
2- Nutrition Science Specialist, LifeandMe Company, Tehran, Iran.
3- BSc in laboratory science, Development and Research Group of LifeandMe Company, Tehran, Iran.
Abstract: (76 Views)
Introduction: Lung cancer is among the most common and fatal cancers worldwide. The majority of cases are diagnosed at advanced stages, leading to poor prognosis and decreased survival rates. Early detection of lung cancer is crucial for improving therapeutic outcomes; however, it is often challenging due to the absence of symptoms in the initial stages of the disease. Therefore, identification of reliable tumor biomarkers is essential to advance early detection strategies. In recent years, next-generation sequencing (NGS) technology has brought a remarkable transformation to the field of oncology. This study aims to evaluate the importance of NGS-based panels in the early diagnosis and personalized treatment of lung cancer.
Materials and Methods: In this review study, the keywords "lung cancer," "next-generation sequencing," "biomarker," "early detection," and "personalized treatment" were utilized. These keywords were searched in online databases including Science Direct, Scopus, NCBI, PubMed, and Google Scholar. This article is based on the results obtained from these searches.
Results: NGS technology plays a pivotal role in the early detection of lung cancer by providing comprehensive genetic profiles and enabling identification of key mutations and genetic alterations. This technology allows clinicians to detect actionable biomarkers and deliver precise, targeted therapies for patients. NGS panels, capable of simultaneous analysis of multiple genes, serve as efficient tools for identifying therapeutic targets and resistance mechanisms. The high throughput of NGS in processing genetic data facilitates more rapid diagnostic results and timely therapeutic decision-making.
Conclusion: As an emerging technology, NGS significantly contributes to the early detection and personalized treatment of lung cancer. By accurately identifying genetic alterations and efficiently profiling patients’ genomes, this technology can help reduce mortality rates and improve the quality of healthcare. With ongoing advancements and expanded clinical application of NGS, a significant transformation in the diagnosis and treatment of lung cancer is anticipated.
Materials and Methods: In this review study, the keywords "lung cancer," "next-generation sequencing," "biomarker," "early detection," and "personalized treatment" were utilized. These keywords were searched in online databases including Science Direct, Scopus, NCBI, PubMed, and Google Scholar. This article is based on the results obtained from these searches.
Results: NGS technology plays a pivotal role in the early detection of lung cancer by providing comprehensive genetic profiles and enabling identification of key mutations and genetic alterations. This technology allows clinicians to detect actionable biomarkers and deliver precise, targeted therapies for patients. NGS panels, capable of simultaneous analysis of multiple genes, serve as efficient tools for identifying therapeutic targets and resistance mechanisms. The high throughput of NGS in processing genetic data facilitates more rapid diagnostic results and timely therapeutic decision-making.
Conclusion: As an emerging technology, NGS significantly contributes to the early detection and personalized treatment of lung cancer. By accurately identifying genetic alterations and efficiently profiling patients’ genomes, this technology can help reduce mortality rates and improve the quality of healthcare. With ongoing advancements and expanded clinical application of NGS, a significant transformation in the diagnosis and treatment of lung cancer is anticipated.
Keywords: Lung Cancer, Next-generation Sequencing, Biomarker, Early Detection, Personalized Treatment.
Type of Study: review |
Subject:
full articles
Received: 2024/12/16 | Accepted: 2025/01/26 | Published: 2025/03/30
Received: 2024/12/16 | Accepted: 2025/01/26 | Published: 2025/03/30
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |